Chimeric Therapeutics Ltd. (AU:CHM) has released an update. Chimeric Therapeutics, a leader in cell therapy, has announced a ...

The first live birth of a chimeric monkey with a high proportion of cells derived from a stem cell line was reported by ...

Chimeric Therapeutics Ltd. (AU:CHM) has released an update. Chimeric Therapeutics made significant strides in its cell therapy programs, enrolling the first patient in its CHM CDH17 Phase 1/2 ...

Chimeric Therapeutics Ltd. (AU:CHM) has released an update. Chimeric Therapeutics Ltd. has announced the issuance of nearly 70 million fully paid ordinary shares for quotation on the Australian ...

Obe-cel was designed to increase T-cell persistence and reduce T-cell exhaustion and was shown to improve response rates and survival, particularly in patients with low leukemia burden.

The Filipino-born artist takes a journey through primordial mud, chimeric worlds, and suppressed psychic demons to honor trans people as channels of divinity.

A recent meta-analysis investigating cardiovascular complications in adults undergoing chimeric antigen receptor (CAR) T-cell ...

Blood cancer is the low-hanging fruit for Chimeric Therapeutics, but the company is targeting more from its next-gen Car-T ...

About Hemogenyx Pharmaceuticals plc Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and ...

INT2104 is a novel in vivo chimeric antigen receptor (CAR) gene therapy designed to generate CAR-T and CAR-NK cells in the patient’s body to target CD20-expressing malignant B cells Interim ...

These findings suggest that KIR2DS2-positive (KIR2DS2+) natural killer (NK) cells could be an attractive therapeutic target ...